logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9624161 B1

PDFFull Text
Expired
Date of Patent:
Apr. 18, 2017

Filed:

Oct. 24, 2014

Estrogen receptor ligands and methods of use thereof

Applicant:

Gtx, Inc., Memphis, TN (US);

Inventors:

James T. Dalton, Ann Arbor, MI (US);

Mitchell S. Steiner, Germantown, TN (US);

Christopher C. Coss, Barlett, TN (US);

Robert H. Getzenberg, Memphis, TN (US);

Assignee:

GTX, INC., Memphis, TN (US);

Attorneys:

Mark S. Cohen

Pearl Cohen Zedek Latzer Baratz LLP

Primary Examiner:

San-Ming Hui

Int. Cl.
CPC ...
A61K 31/165 (2006.01); C07C 235/64 (2006.01); C07C 233/75 (2006.01); C07C 215/50 (2006.01); C07C 215/82 (2006.01); A61K 45/06 (2006.01); A61K 31/167 (2006.01); A61K 31/137 (2006.01); A61K 31/136 (2006.01); C07D 295/088 (2006.01);
U.S. Cl.
CPC ...
C07C 235/64 (2013.01); A61K 31/136 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 45/06 (2013.01); C07C 215/50 (2013.01); C07C 215/82 (2013.01); C07C 233/75 (2013.01); C07D 295/088 (2013.01);
Abstract

The present invention relates to methods for reducing testosterone levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.

Find Patent Forward Citations

Dalton, James. (2017). Estrogen receptor ligands and methods of use thereof (U.S. Patent No. 9624161). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9624161

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…